

**The Genetics of Kidneys in Diabetes  
(GOKIND) Study**

# **GOKIND**

## **MANUAL OF OPERATIONS**

**Phase I GOKIND**

**6th Edition May 2006**

**JDRF Coordinating Center  
The Biostatistics Center  
The George Washington University  
6110 Executive Boulevard  
Suite 750  
Rockville, Maryland 20852**

# **GOKIND Manual of Operations**

## **TABLE OF CONTENTS - OVERVIEW**

### **LIST OF ABBREVIATIONS**

### **SECTIONS**

- 1. HOW TO GET STARTED AS A NEW SITE**
- 2. RECRUITMENT AND SCREENING PROCEDURE**
- 3. GUIDELINES FOR OBTAINING INFORMED CONSENT**
- 4. SCREENING BASELINE VISIT**
- 5. QUALITY CONTROL AND INTERNAL MONITORING**
- 6. GOKIND FORMS COMPLETION AND MAILING OF FORMS**
- 7. REIMBURSEMENT**
- 8. LABORATORY SPECIMENS AND THE CENTRAL BIOCHEMISTRY LABORATORY**
- 9. CDC PROCEDURES FOR GENOTYPE DETERMINATION**
- 10 GOKIND DATA COLLECTION AND INFORMATION TRANSFER**

### **APPENDICES**

- 1. HIPPA INFORMATION**
- 2. GOKIND FORMS**
- 3. INFORMED CONSENT TEMPLATE**

# GOKIND Manual of Operations

## TABLE OF CONTENTS

### LIST OF ABBREVIATIONS

<b>1. HOW TO GET STARTED AS A NEW SITE.....</b>	<b>1-1</b>
1.1 Introduction.....	1-1
1.2 IRB Approval Procedure .....	1-1
1.2.1 IRB Procedure for Sites With Multiple Project Assurance (MPA).....	1-1
1.2.2 IRB Procedure for Sites Without Multiple Project Assurance.....	1-1
1.3 Identification of Study Coordinator.....	1-1
1.4 Space Requirement for Study Coordinator and Study Documents.....	1-2
1.5 Other Equipment Requirements .....	1-2
1.6 Legal Agreement With The George Washington University.....	1-2
1.7 Certification Process.....	1-3
1.8 Certification Numbers .....	1-3
1.9 Certification of New Personnel at a Certified Site .....	1-3
Table 1.1 Federal Wide Assurance of Protection for Human Subjects .....	1-4
<b>2. RECRUITMENT AND SCREENING PROCEDURE.....</b>	<b>2-1</b>
2.1 Introduction.....	2-1
2.2 The GOKIND Study Sites .....	2-1
2.3 The GOKIND Study Participant Recruitment.....	2-1
2.3.1 Promotional Materials Development.....	2-1
2.3.2 National Media Outreach.....	2-2
2.3.3 Direct Mail Programs .....	2-2
2.3.4 Outreach Campaign and Technical Assistance to Local Sites .....	2-2
2.3.5 Operation of a North American Toll-Free Call Center and Participant Database....	2-3
2.3.6 Coordination of Recruiting Complete Trios.....	2-5
2.4 Identification of Candidate Probands.....	2-5
2.4.1 Eligibility and Exclusion Criteria.....	2-5
2.4.1.1. Definitions for Inclusion Into the Study .....	2-5
2.4.1.2. Definitions for Exclusion From the Study .....	2-6
Table 2.1 JDRF Patient Screening Questionnaire .....	2-8
<b>3. GUIDELINES FOR OBTAINING INFORMED CONSENT.....</b>	<b>3-1</b>
3.1 Informed Consent .....	3-1
<b>4. SCREENING BASELINE VISIT .....</b>	<b>4-1</b>
4.1 Introduction.....	4-1
4.2 Preparation .....	4-1
4.3 Reception .....	4-1
4.4 Review Purpose of Study and Study Requirements .....	4-2

4.5	Informed Consent .....	4-2
4.6	Review of Exclusion Criteria .....	4-3
4.7	Baseline Visit .....	4-3
4.8	Physical Measures .....	4-3
4.8.1	Blood Pressure .....	4-3
4.8.2	Hypertension .....	4-4
4.8.3	Guidelines for Measuring Weight, Stature, and Circumference .....	4-4
4.8.3.1.	Weight .....	4-4
4.8.3.2.	Stature .....	4-4
4.8.3.3.	Circumference Measurements .....	4-5
4.8.3.3.1.	Natural Waist .....	4-5
4.8.3.3.2.	Iliac Crest Waist .....	4-6
4.9	Baseline Blood, Urine, and DNA Samples .....	4-6
4.10	Screening for Persistent Proteinuria .....	4-6
4.11	Screening for Persistent Normoalbuminuria .....	4-6
4.12	Information Feedback .....	4-7
Table 4.1	List of Medications .....	4-8
Table 4.2	Classification of Blood Pressure for Adults Aged 18 Years and Older .....	4-9
Figure 4.1	Letter to physician .....	4-10
Figure 4.2	Report of Biochemical Results for Clinic and Participant .....	4-11
Figure 4.3	Report on Proband Eligibility for GOKIND Baseline Status .....	4-12
Figure 4.4	GOKIND Guidelines for Interpreting Laboratory Data .....	4-13
<b>5.</b>	<b>QUALITY CONTROL AND INTERNAL MONITORING .....</b>	<b>5-1</b>
5.1	General Principles .....	5-1
5.1.1	Methods in GOKIND .....	5-1
5.2	Performance Monitoring .....	5-1
5.2.1	Clinical Centers .....	5-1
5.2.2	Central Units .....	5-1
Table 5.1	Measurements and Methods in GOKIND .....	5-3
Table 5.2	GOKIND Overview of QC Monitoring .....	5-4
Table 5.3	Quarterly Quality Control Summary of Genotypic Data for the GOKIND Study .....	5-5
<b>6.</b>	<b>GOKIND FORMS COMPLETION AND MAILING OF FORMS .....</b>	<b>6-1</b>
6.1	The Study Forms .....	6-1
6.2	Form Supplies .....	6-1
6.3	Form, Patient, and Visit Identifying Information .....	6-1
6.3.1	Form Number and Version Number .....	6-1
6.3.2	Identifying Information .....	6-2
6.3.3	Clinic Number .....	6-2
6.3.4	Family Identification Number and Proband/Relative Code .....	6-2
6.3.5	Proband/Relative's Initials .....	6-2
6.3.6	Date of Visit .....	6-2
6.4	Completing Forms .....	6-3
6.5	Batching and Mailing .....	6-3
6.5.1	Inventorying Forms .....	6-3

6.5.2	Batching Forms .....	6-3
6.5.3	Mailing Forms .....	6-3
6.6	Receipt of Forms .....	6-4
6.7	Editing Data on Forms .....	6-4
Table 6.1	GOKIND Forms Listing .....	6-6
Table 6.2	List of GOKIND Centers and Clinic Numbers .....	6-7
Table 6.3	GOKIND Study Week Numbers for Year 1 Through Year 3 .....	6-8
Figure 6.1	GOKIND Edit Message Report.....	6-12
<b>7.</b>	<b>REIMBURSEMENT .....</b>	<b>7-1</b>
7.1	Introduction.....	7-1
7.2	Payments for Follow-Up .....	7-1
<b>8.</b>	<b>LABORATORY SPECIMENS AND THE CENTRAL BIOCHEMISTRY LABORATORY .....</b>	<b>8-1</b>
8.1	Introduction.....	8-1
8.2	Preparation .....	8-1
8.2.1	Participant Contact .....	8-1
8.2.2	Supplies Provided by the CBL .....	8-1
8.2.3	Blood Collection Tray and Tubes.....	8-2
8.2.3.1.	Blood Collection Tray.....	8-2
8.2.3.2.	Blood Collection Tubes .....	8-2
8.2.4	Venipuncture .....	8-2
8.3	Collection of Genetic Specimens – Tubes 1, 2, and 3 .....	8-4
8.3.1	Scheduling.....	8-4
8.3.2	Collecting, Labeling, and Storing .....	8-5
8.4	Hemoglobin A1C, Saved Plasma, and Packed Red Cells .....	8-5
8.4.1	Hemoglobin A1C Labeling, Processing, and Storing .....	8-5
8.4.2	Saved Plasma Labeling, Processing, and Storing .....	8-6
8.4.3	Packed Cells Labeling, Processing, and Storing .....	8-6
8.5	Collection of Lipids (Cholesterol and HDL Cholesterol), Creatinine, Cystatin C, and Saved Serum – Tube 4 .....	8-7
8.6	Random Urine Collection and Processing .....	8-7
8.6.1	Urine Specimen Collection for Albumin/Creatinine Ratio (ACR).....	8-7
8.6.2	Urine Aliquotting .....	8-7
8.6.3	Screening Cases and Controls .....	8-8
8.7	Packaging, Shipping and Storage of Specimens .....	8-9
8.7.1	Packaging of Genetic Tubes (Tubes #1, #2, and #3) .....	8-9
8.7.2	Packaging of Refrigerated Hemoglobin A1c Specimens .....	8-10
8.7.3	Packaging of Frozen Specimens .....	8-10
8.8	GOKIND Clinic Remote Site Collections .....	8-11
8.8.1	GOKIND Clinic Responsibilities.....	8-11
8.8.2	Proband/Parent Responsibilities.....	8-12
8.8.3	Local Provider and/or Laboratory Responsibilities.....	8-13
8.8.3.1	Blood/Urine Collection and Processing.....	8-13
8.8.3.2	Specimen Packing and Shipping .....	8-14
8.9	CTI Remote Site Collections .....	8-14

8.9.1 CTI Responsibilities .....	8-14
8.9.1.1 Screening for Cases and Controls .....	8-15
8.9.2 CTI Homecare Responsibilities .....	8-16
8.9.2.1 Blood/Urine Collection and Processing .....	8-16
8.9.2.2 Specimen Packing and Shipping .....	8-17
8.10 Priority Collections for All Sites .....	8-17
8.11 Quality Control .....	8-18
8.12 Mailing Instructions to the CBL .....	8-18
8.13 Storage of Specimens .....	8-18
8.14 Specimen Identification .....	8-19
Figure 8.1 GOKIND Label .....	8-20
Figure 8.2 Applying the GOKIND Label to the Sample Tube .....	8-21
Figure 8.3 Explanation of GOKIND Labels .....	8-22
Figure 8.4 GOKIND Labels .....	8-25
GOKIND Central Biochemistry Laboratory Flow Chart .....	8-28
GOKIND Central Biochemistry Laboratory Flow Chart: Remote Collection .....	8-29

## **9. CDC PROCEDURES FOR GENOTYPE DETERMINATION .....**

Insulin .....	(25pp)
DRB1 .....	(32pp)
DQA1 .....	(25pp)
DQB1 .....	(32pp)

## **10. GOKIND DATA COLLECTION AND INFORMATION TRANSFER .....**

10.1 Overview of GOKIND Data Collection .....	10-1
10.2 Matthews Media Group .....	10-1
10.3 Clinics .....	10-2
10.4 CBL .....	10-2
10.5 Joslin .....	10-3
10.6 CDC AND CASPIR .....	10-3
10.6.1 Definition for CDC Genetics Data .....	10-3
10.6.1.1 HLA Library Release code .....	10-4
10.6.1.2 HLA Genotypes that include an "X" .....	10-4
10.6.2 CASPIR .....	10-4
10.7 BRITISH DIABETES ASSOCIATION – DIABETES UK .....	10-4
10.8 GWU .....	10-4
10.8.1 Biochemical Data Reports .....	10-4
10.8.2 Eligibility Reports .....	10-5
10.8.3 Reconciliation of Mailing Forms and General Forms .....	10-5
10.8.4 Personal Information – Identifiable Participant Data .....	10-5
10.8.5 Specimen Tracking System .....	10-5
10.8.6 GWU COC Data Receipt Summary .....	10-6
Figure 10.1 GOKIND Electronic Data Collection .....	10-7
Figure 10.2 GOKIND Data Collection .....	10
Figure 10.3 Report of Biochemical Results for Participant and Clinic .....	10
Figure 10.4 GoKinD Guidelines for Interpreting Laboratory Results .....	10

Figure 10.5 Report on Proband Eligibility for GOKIND Baseline Status .....	10
--	----

## **APPENDIX**

Appendix 1 – HIPAA Information .....	
Appendix 2 – GOKIND Forms .....	
Appendix 3 – Informed Consent Template .....	